ALKS - Alkermes PLC Stock Price, Fair Value and News

$29.54+0.57 (+1.97%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ALKS Price Action

Last 7 days

-0.6%

Last 30 days

-2.1%

Last 90 days

2.1%

Trailing 12 Months

0.2%

ALKS RSI Chart

ALKS Valuation

Market Cap

4.9B

Price/Earnings (Trailing)

14.4

Price/Sales (Trailing)

3.21

EV/EBITDA

9.88

Price/Free Cashflow

9.94

ALKS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ALKS Fundamentals

ALKS Revenue

Revenue (TTM)

1.5B

Rev. Growth (Yr)

4.24%

Rev. Growth (Qtr)

0.9%

ALKS Earnings

Earnings (TTM)

338.8M

Earnings Growth (Yr)

-10.41%

Earnings Growth (Qtr)

-4.98%

ALKS Profitability

EBT Margin

26.36%

Return on Equity

19.55%

Return on Assets

14.54%

Free Cashflow Yield

10.06%

ALKS Investor Care

Shares Dilution (1Y)

2.05%

Diluted EPS (TTM)

2.02

ALKS Alerts

1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	1.5B	1.5B	1.5B	0
2024	1.7B	1.5B	1.5B	1.6B
2023	1.1B	1.5B	1.6B	1.7B
2022	1.2B	1.2B	1.1B	1.1B
2021	1.0B	1.1B	1.1B	1.2B
2020	1.2B	1.2B	1.2B	1.0B
2019	1.1B	1.1B	1.1B	1.2B
2018	936.7M	1.0B	1.1B	1.1B
2017	780.7M	804.4M	841.5M	903.4M
2016	623.9M	667.7M	695.3M	745.7M
2015	649.8M	647.7M	640.4M	628.3M
2014	563.1M	577.9M	598.1M	618.8M
2013	575.5M	561.9M	577.8M	596.3M
2012	390.0M	480.3M	532.3M	542.6M
2011	186.6M	219.3M	242.1M	331.8M
2010	0	0	0	183.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Alkermes PLC

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

CEO	Mr. Richard F. Pops
WEBSITE	alkermes.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	2280

Alkermes PLC Frequently Asked Questions

What is the ticker symbol for Alkermes PLC? What does ALKS stand for in stocks?

ALKS is the stock ticker symbol of Alkermes PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alkermes PLC (ALKS)?

As of Wed Dec 03 2025, market cap of Alkermes PLC is 4.88 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALKS stock?

You can check ALKS's fair value in chart for subscribers.

Is Alkermes PLC a good stock to buy?

The fair value guage provides a quick view whether ALKS is over valued or under valued. Whether Alkermes PLC is cheap or expensive depends on the assumptions which impact Alkermes PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALKS.

What is Alkermes PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ALKS's PE ratio (Price to Earnings) is 14.4 and Price to Sales (PS) ratio is 3.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALKS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alkermes PLC's stock?

In the past 10 years, Alkermes PLC has provided -0.087 (multiply by 100 for percentage) rate of return.